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Structured abstract 
Background: Recent reports have provided evidence that bridging therapy with low-molecular-
weight heparin (LMWH) may increase bleeding complications in patients with atrial fibrillation 
(AF) on oral anticoagulation undergoing percutaneous coronary intervention (PCI). We sought to 
assess mid-term bleeding and thromboembolic events in patients from the AFCAS registry 
discharged on triple therapy (TT).  
Methods: AFCAS is a multicenter, prospective registry enrolling patients with AF undergoing PCI. 
The primary endpoints were: 1) bleeding complications as defined by the bleeding academic 
research criteria (BARC); 2) a composite of cardiac and cerebrovascular events (MACCE) at 3 and 
12 months follow-up.  
Results: Altogether 663 out of 929 consecutive patients were discharged on TT, either on oral 
vitamin K antagonist (VKA-TT) (n=498) or bridging LMWH-TT (n=165). Patients on LMWH-TT had 
more often diabetes, heart failure, and hypertension compared to those on VKA-TT. The rates of 
major bleeding events (BARC ≥3) (11.5% vs. 6.0%, p=0.03) as well as MACCE (11.5% vs. 5.0%, 
p=0.006) were higher in the LMWH-TT group compared to VKA-TT group at 3 months follow-up. 
In a Cox multivariate regression model and propensity-score matched analysis LMWH-TT 
increased the risk for major BARC bleeding events at 3 and 12 months follow-ups.  
Conclusions: In this large, prospective, real-world population of patients with AF undergoing PCI 
patients discharged on LMWH-TT had a significantly higher risk for major bleeds in comparison 
to patients discharged on VKA-TT. LMWH-bridging therapy appeared harmful in this subset of 
patient on oral anticoagulation. 
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Introduction  
In accordance with current guidelines, the antithrombotic therapy for patients with atrial 
fibrillation (AF) undergoing percutaneous coronary intervention with stent implantation (PCI) 
should consist of triple therapy (TT) of vitamin K-antagonist (VKA), aspirin, and clopidogrel when 
the thromboembolic risk is moderate to high (CHA2DS2VASC score ≥2) 
1. TT is the treatment of 
choice at least in the first month after stent implantation 1, 2. Data on patients after PCI who 
have an indication for VKA are limited 3, 4. Previously bridging treatment with low-molecular-
weight heparin (LMWH) has been the standard recommendation for patients if VKA has to be 
interrupted or introduced5, 6.  However, recent expert recommendations suggest that in 
patients on oral anticoagulation with CHA2DS2-VASc ≥2 and stable angina, an uninterrupted 
anticoagulation strategy with no additional heparin boluses during PCI is the preferred strategy 
(Class IIa, level of evidence C)1. Little is known about the outcomes of LMWH-bridging therapy in 
long-term follow-up as well as in patients presenting with acute coronary syndrome.  
 In this pre-specified analysis, we prospectively assessed the effect of LMWH-bridging 
therapy vs. uninterrupted oral anticoagulation therapy on thrombotic and bleeding events in 
patients with AF undergoing stent implantation with an indication for TT.  
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Methods 
Study population 
AFCAS is an observational, multicenter, prospective registry including patients with AF 
who are referred for PCI (Clinicaltrials.gov identifier NCT00596570). Inclusion criteria were 
elective or urgent/emergency PCI and 1) history of AF (paroxysmal, persistent, or permanent), 
or 2) AF during the index hospital stay. Because of the observational design, the only exclusion 
criterion was unwillingness/inability to participate in the study or to give written informed 
consent. Coronary angiography and PCI were performed using either radial or femoral approach 
for arterial access and haemostasis was obtained according to the local practice. Lesions were 
treated according to contemporary interventional techniques.  
LMWH (enoxaparin sodium, dalteparin), unfractionated heparin, bivalirudin and 
glycoprotein IIb/IIIa inhibitors were administered entirely at the operator’s discretion. 
Moreover, the choice of the combination of antithrombotic treatment after the procedure was 
at the treating physician’s discretion. 
Details of the study have been published elsewhere 7-10. At each participating center, 
patients were treated according to local policies, and were followed up for 12 months (phone 
call at 3, 6 and 12 months and when needed by assessment of patient records in the hospitals 
and in health centers of catchment areas. Each event was adjudicated according to the pre-
specified definitions for myocardial infarction, target vessel revascularization, stent thrombosis 
transient ischemic attack and stroke 7-10. Bleeding events were centrally adjudicated based on 
the patient record data on case report forms. The study complied with the Declaration of 
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Helsinki. Ethic committees of participating centers approved the study protocol, and written 
informed consent was obtained from every patient.  
This analysis included patients discharged on TT including VKA, aspirin and clopidogrel 
(VKA-TT) and those on LMWH–bridging therapy, aspirin and clopidogrel (LMWH-TT).  
Study endpoints 
Endpoints included any bleeding complications defined according to the bleeding 
academic research consortium (BARC) criteria as any (BARC 2-5), minor (BARC 2) and major 
(BARC 3a, 3b, 3c and 5)11; a composite of major adverse cardiac and cerebrovascular events 
(MACCE) and its derivatives all-cause mortality, non-fatal myocardial infarction, stent 
thrombosis according ARC criteria12, repeat revascularization (excluding staged planned 
procedures), and arterial embolism (stroke, transient ischaemic attack, peripheral arterial 
embolism). 
Statistical analysis 
Data are presented as means ± standard deviations, median [interquartile range] and 
frequencies (%) where appropriate. Normality was tested using Kolmogorov-Smirnov and 
Shapiro-Wilk tests. Continuous variables were analyzed using independent samples t-test and 
independent samples Mann-Whitney U test where appropriate. Categorical variables were 
analyzed using chi-square tests. Cox regression analysis was performed using stepwise 
backward Wald method. The study groups significantly differed in a number of baseline and 
procedural characteristics. Such differences were accounted for propensity score analysis. A 
propensity score was estimated by logistic regression initially including all baseline and 
operative variables and after that by a stepwise backward method. The area under the receiver 
operating characteristic (ROC) curve was used to represent the discriminatory ability of the 
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regression model. Propensity score was used for risk adjustment as a covariate in multivariate 
analyses assessing all predefined outcome end-points. Furthermore, one-to-one propensity 
score matching was performed by using a caliper of 0.02 of the standard deviation of propensity 
score. Significance was set at p value <0.05. Analysis was performed with SPSS version 16.0 
(SPSS Inc., Chicago, IL). 
Results 
Out of 663 patients discharged on TT, 498 (75.1%) were on VKA-TT and remaining 165 
(24.9%) on LMWH-TT. Baseline and procedural characteristics according to VKA-TT vs. LMWH-TT 
are presented in Tables 1 and 2. Median [IQR] dosage of LMWH per day was 100 [60] mg (mean 
SD 107±41 mg) in patients in the LMWH-TT arm. The use of glycoprotein 2b/3a inhibitors was 
(11.6% vs. 31.5%, p<0.001) and bivalirudin (5.5% vs. 0.6%, p=0.006) in the VKA-TT and LMWH-TT 
arms, respectively. Patients on VKA-TT had less often hypertension, diabetes, and congestive 
heart failure; but more often permanent/persistent AF. Patients on LMWH-TT had higher 
CHA2DS2-VASc-score and modified HAS-BLED-score and more often a history of peptic ulcer. 
However, no differences were found in the indication for PCI, left ventricular ejection fraction or 
the use of drug-eluting stents. As expected, periprocedural INR was significantly higher in 
patients on VKA-TT compared to those on LMWH-TT at discharge. The median [IQR] duration of 
hospital stay was longer in patients on LMWH-TT compared to those on VKA-TT (3.0 [5.0] days 
vs. 2.0 [4.0] days, p<0.001). In patient on LMWH-TT, the median interruption of VKA therapy 
was 5.5 [12.0] days (mean 10.4 ± 14.6 days), and 66/162 (40.7%) of them had VKA treatment re-
initiated at the time of hospital discharge.    
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Adverse events at 3 months as well as 12 months follow-up are presented in Table 3. The 
rate of major bleeding events (BARC ≥3) was significantly higher in the LMWH-TT group 
compared to VKA-TT group at 3 months follow-up. The rate of MACCE was also significantly 
higher in the LMWH-TT group compared to VKA-TT group. Figure 1 presents the freedom from 
major bleeding at 3 months follow-up and Figure 2 freedom from MACCE at 12 months follow-
up. Patients on LMWH-TT group had more major bleeding events early within 30 days after the 
index procedure compared to those on VKA-TT. A significant difference in the occurrence of 
MACCE was also observed throughout the entire follow-up.  
Since the study groups differed significantly in certain baseline characteristics as shown 
in Tables 1 and Table 2, a multivariate Cox-regression analysis adjusted for the presence of 
diabetes, hypertension, congestive heart failure, renal impairment, anemia, the use of 
bivalirudin or glycoprotein 2b/3a inhibitors, and acute coronary syndrome was carried out. 
Here, LMWH-TT remained a significant predictor for major BARC bleeding events at 3 months 
(HR 3.51, 95%CI 1.76-6984, p<0.001) and at 12 months follow-up (HR 2.22, 95%CI 1.04-3.06, 
p=0.007), respectively. LMWH-TT was also significantly associated with increasing rate of 
MACCE at 3 months (HR 2.73, 95%CI 1.47-5.09, p=0.002) persisting up to 12 months follow-up 
(HR 1.72, 95%CI 1.24-3.97, p=0.008). Multivariate models remained unchanged when patients 
on periprocedural bivalirudin or glycoprotein 2b/3a inhibitors were excluded (data not shown). 
Propensity score analysis 
To further adjust for baseline differences, a propensity score was calculated by logistic 
regression (Hosmer-Lemeshow test: p=0.173) and had an area under the ROC curve of 0.880 
(95%CI 0.844-0.915). The matching caliper chosen was 0.05. One-to-one propensity score 
matching provided 76 pairs with similar baseline and operative characteristics (Tables 1-3).  
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Patients discharged on LMWH-TT showed an increased (non-significant) risk for major 
bleeding at 3 months (HR 3.45, 95%CI 0.95-12.6, p=0.06), and 12 months (HR 2.97, 95%CI 0.95-
9.34, p=0.06) (Table 3). Similarly, LMWH-TT was associated with a non-significant increased risk 
of MACCE at 12 months (21.3% vs. 13.5%, p=0.191), driven by trends to increased mortality 
(10.5% vs. 4.2%, p=0.229) and repeat revascularization (10.4% vs. 4.2%, p=0.166) (Table 3). 
Propensity score adjusted analysis showed that at 12 months, the risk of mortality 
(p=0.637), myocardial infarction (p=0.601), repeat revascularization (p=0.109), stent thrombosis 
(p=0.678), arterial thromboembolism (p=0.192) and MACCE (p=0.409) were similar between the 
study groups.  
Discussion 
 Bridging therapy with LMWH in addition to dual antiplatelet therapy appeared to 
increase the rate of major bleeding events compared to uninterrupted oral VKA-TT in this “real 
world” registry of patients with AF undergoing PCI. Moreover, LMWH-TT was associated with 
increased rate of thrombotic/thromboembolic events and prolonged hospital stay, and a 3-fold 
increase of bleeding events in the propensity score matched model.  
Anticoagulation therapy is recommended in patients with AF and a moderate to high risk 
for strokes as defined by a CHA2DS2-VASC-score ≥2 to avoid stroke and other thromboembolic 
events 1. In patients undergoing PCI with stent implantation, clinical decision-making is 
challenging since the combination of aspirin and a P2Y12-inhibitor is also indicated to prevent 
stent thrombosis. TT should always be considered to carry an increased risk of overall bleeding 
and should therefore be reserved for those patients for whom the expected net clinical benefit 
is favorable. Consequently, guidelines recommend in patients with an indication for oral 
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anticoagulation after PCI the combination of VKA, aspirin and clopidogrel (VKA-TT) for at least 
one month, although risk for severe bleedings increases substantially under VKA-TT1. In 
addition, VKA plus clopidogrel treatment may be considered in patients at low bleeding risk 1, 13. 
Recent randomized trials showed that uninterrupted oral anticoagulation therapy was 
associated with substantially decreased 0.19-fold risk in the rate of major bleeding events after 
pacing-device implantation 14 and 0.08-fold risk in the catheter ablation of AF compared to 
bridging therapy 15. There are, however, no randomized trials assessing the safety or risks of 
bridging therapy during PCI. In the earlier non-randomized studies, the strategy of 
uninterrupted oral anticoagulation has been at least as safe as warfarin pause combined with 
heparin bridging, but the low methodological quality of studies precludes any definitive 
conclusions 4, 16.  The present analysis gives important additional information on this topic. It is 
the first to focus on patients with an indication for TT and also assess the 1-year outcome of the 
patients using also propensity score-matching to adjust for differences in the patient groups.  
Our study supports the view that uninterrupted oral anticoagulation strategy should be 
preferred in patients on VKAs. Warfarin prolongs activated clotting time (ACT) in a predictable 
fashion. In addition, therapeutic (International Normalized Ratio (INR) ≥2.0) uninterrupted 
anticoagulation with warfarin is not associated with increased periprocedural thromboembolic 
or bleeding complications in patients who underwent PCI17. Large INR fluctuations after VKA 
interruption and suppression of proteins C and S occurring upon VKA re-initiation can be 
avoided using uninterrupted oral anticoagulation. In line with previous reports, the incidence of 
bleeding and thromboembolic complications appeared to increase during the early varying 
phase of anticoagulation. LMWH-bridging seems also to be less advantageous from an economic 
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point of view since hospital stay was significantly longer in patients on LMWH-TT compared to 
those on VKA-TT in line with a previous report18. 
Finally, the question of whether uninterrupted oral anticoagulation is associated with a 
higher risk of bleeding because of difficulties in controlling haemorrhage appears not valid, 
because rapid reversal of anticoagulation can be obtained using plasma and/or coagulation 
proteins. Of note, reversal of the anticoagulant effect of enoxaparin and fondaparinux, which 
are the recommended anticoagulants in acute coronary syndromes, may be more cumbersome, 
since protamine sulphate (the established antidote to unfractionated heparin) has little or no 
effect in neutralizing these agents.  
Limitations  
Significant baseline differences between the study groups were accounted using 
multivariate Cox regression modeling and propensity score matched pairs. The large differences 
between the study populations led to a propensity score with a rather large under the ROC 
curve. This in turn led to a reduced, but very tightly matched pairs. The difference between the 
results of multivariate analysis and propensity-adjusted analysis could be due to a reduced 
number of patients available for propensity score calculation as well as the fact that propensity 
score has dealt with a much larger number of variables. Nevertheless, major bleeding events 
were more frequent with all these methods.  
Conclusion 
In this large, prospective, real-world population of patients with AF undergoing PCI 
patients discharged on LMWH-TT had a significantly higher risk for major bleeds in comparison 
to patients discharged on VKA-TT. LMWH-bridging therapy appeared harmful in this subset of 
patient on oral anticoagulation.  
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Table 1 Baseline clinical characteristics of the two study subgroups 
 
 
Whole cohort  
Propensity score matched 
pairs 
 
Variable VKA-TT 
(n = 498) 
LMWH-TT 
(n = 165) 
p-
value 
VKA-TT 
(N=76) 
LMWH-TT 
(N=76) 
p 
value 
Age (years) 74.0 [10] 73.0 [9] 0.30 74.0 [13] 74.0 [8] 0.588 
Female gender 
146 
(29.3) 
45 (27.3) 0.69 21 (27.6) 19 (25.0) 0.713 
Diabetes mellitus 
161 
(32.3) 
84 (50.9) <0.001 32 (42.1) 32 (42.1) 1.000 
Hypercholesterolemia 
338 
(67.9) 
111 (67.3) 0.92 47 (61.8) 53 (69.7) 0.393 
Body mass index (kg/m2) 27.8 [6.0] 28.0 [6.3] 0.45 28.3 [7.1] 28.1 [6.7] 0.956 
Current or ex-smoking 43 (8.6) 26 (15.8) 0.01 5 (6.6) 9 (11.8) 0.401 
Hypertension 
397 
(79.7) 
158 (95.8) <0.001 70 (92.1) 73 (96.1) 0.303 
Paroxysmal atrial fibrillation 
137 
(27.5) 
78 (47.3) <0.001 31 (40.8) 31 (40.8) 1.000 
CHA2DS2-VASC score 4.0 [2.0] 5 [2.0] 0.004 5.0 [2.0] 4.0 [6.0] 0.721 
HAS-BLED score 3.0 [1.0] 3.0 [0] 0.007 3.0 [0] 3.0 [0] 0.145 
History of peptic ulcer 15 (3.0) 13 (7.9) 0.01 2 (2.6) 7 (9.2) 0.167 
History of cerebral 
haemorrhage 
4 (0.8) 1 (0.6)) 1.0 0 0 - 
History of GI haemorrhage 11 (2.2) 4 (2.4) 0.77 1 (1.3) 1 (1.3) 1.000 
History of heart failure 80 (16.1) 54 (32.7) <0.001 29 (38.2) 24 (31.6) 0.395 
eGFR below 60 ml/min 
135 
(33.3) 
57 (39.3) 0.22 24 (35.8) 28 (39.4) 0.661 
Pre-procedural anemia 
(WHO) 
131 
(29.2) 
45 (28.0) 0.84 3 (3.9) 1 (1.3) 0.620 
Prior transient ischaemic 
attacks 
28 (5.6) 4 (2.4) 0.14 6 (7.9) 2 (2.6) 0.276 
Prior stroke  68 (13.7) 16 (9.7) 0.22 10 (13.2) 10 (13.2) 1.000 
Prior MI 
126 
(25.3) 
38 (23.0) 0.60 22 (28.9) 17 (22.4) 0.353 
Prior PCI 70 (14.1) 34 (20.6) 0.05 9 (11.8) 17 (22.4) 0.085 
Prior coronary bypass 
surgery 
82 (16.5) 19 (11.5) 0.14 12 (15.8) 11 (14.5) 0.821 
Left ventricular ejection 
fraction (%) 
50 [20] 50 [25] 0.55 47 [21] 50 [18] 0.429 
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Stable angina pectoris 
228 
(45.8) 
88 (53.3) 0.86 39 (51.3) 37 (48.7) 0.746 
ACS       
    Unstable angina pectoris 76 (15.3) 30 (18.2) 0.39 13 (17.1) 19 (25.0) 0.233 
    Non-ST-elevation MI 
129 
(25.9) 
38 (23.0) 0.54 18 (23.7) 14 (18.4) 0.426 
    ST-elevation MI 65 (13.1) 20 (12.1) 0.89 6 (7.9) 6 (7.9) 1.000 
       
Continuous variables are presented as median [interquartile range], whereas categorical variables are presented as frequency (percentage). 
ACS indicates acute coronary syndrome; eGFR: estimated glomerular filtration rate; GI: gastrointestinal, IQR: inter-quartile range; MI: 
myocardial infarction; PCI: percutaneous coronary intervention. TT: Triple Therapy consisting of anticoagulation, aspirin and clopidogrel. 
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Table 2 Procedural data of the two study subgroups 
 
Whole cohort  
Propensity score matched 
pairs 
 
Variable VKA-TT 
(n = 498) 
LMWH-TT 
(n = 165) 
p-value 
VKA-TT 
(N=76) 
LMWH-TT 
(N=76) 
p 
value 
Femoral access 315 (63.3) 144 (87.3) <0.001 61 (80.3) 67 (88.2) 0.182 
Number of treated 
vessels 
1 [0] 1 [0] 0.77 1.0 [0] 1.0 [0] 0.120 
Drug-eluting stent 119 (25.0) 35 (21.5) 0.40 22 (29.3) 20 (26.3) 0.679 
Plain balloon angioplasty 28 (5.6) 1 (0.6) 0.004 4 (5.3) 0 0.120 
Peri-procedural INR 2.1 [1.0] 1.6 [1.0] <0.001 1.7 [1.0] 1.4 [1.0] 0.193 
Stent diameter (mm) 3.0 [0.5] 3.0 [0.5] <0.001    
Total stent length (mm) 19 [15] 18 [14] 0.45 21.0 [17.0] 18.0 [9.0] 0.017 
Procedural success 487 (97.8) 160 (97.0) 0.48    
 
Continuous variables are presented as mean ± SD or median [interquartile range], whereas categorical variables are presented as frequency 
(percentage). INR: international normalized ratio; TT: Triple Therapy consisting of anticoagulation, aspirin and clopidogrel. 
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Table 3 Clinical outcome at 3 and 12-month follow-up in the two study subgroups 
 
Whole cohort 
 
Propensity score matched 
pairs 
 
Variable 
VKA-TT 
(n = 498) 
LMWH-TT 
(n = 165) 
p-value 
VKA-TT 
(N=76) 
LMWH-TT 
(N=76) 
p value 
 
3 months 
      
Any bleeding (BARC 2-5) 59 (11.8) 27 (16.4) 0.14 7 (9.1) 15 (19.7) 0.065 
Major bleeding (BARC 3a, 3b, 3c, 
5) 
30 (6.0) 19 (11.5) 0.03 3 (3.9) 10 (13.2) 0.078 
Minor bleeding (BARC 2) 29 (5.8) 8 (4.8) 0.85 4 (5.3) 5 (6.6) 1.000 
MACCE 25 (5.0) 19 (11.5) 0.006 3 (3.9) 8 (10.5) 0.209 
All-cause mortality 13 (2.6) 9 (5.5) 0.08 1 (1.3) 3 (3.9) 0.620 
Non-fatal myocardial infarction 11 (2.2) 4 (2.4) 0.77 2 (2.6) 2 (2.6) 1.000 
Definite/probable stent 
thrombosis 
1 (0.2) 3 (1.8) 0.05 0  (0) 0 (0) - 
Repeat revascularization 3 (0.6) 9 (5.5) <0.001 1 (1.3) 3 (3.9) 0.620 
Stroke/TIA/Arterial embolism 1 (0.2) 2 (1.2) 0.16 0 (0) 1 (1.3) 1.000 
 
12 months 
      
Any bleeding (BARC 2-5) 83 (16.7) 32 (19.4) 0.41 14.9% 24.0% 0.138 
Major bleeding (BARC 3a, 3b, 3c, 
5) 
46 (9.2) 22 (13.3) 0.14 4.5% 16.6% 0.034 
Minor bleeding (BARC 2) 38 (7.6) 10 (6.1) 0.60 9.9% 8.7% 0.884 
MACCE 86 (17.3) 48 (29.1) 0.002 13.5% 21.3% 0.191 
All-cause mortality 44 (8.8) 18 (10.9) 0.44 5.3% 10.5% 0.229 
Non-fatal myocardial infarction 32 (6.4) 9 (5.5) 0.85 2.7% 4.3% 0.618 
Definite/probable stent 
thrombosis 
4 (0.8) 4 (2.4) 0.11 1.4% 0% 0.331 
Repeat revascularization 27 (5.4) 27 (16.4) <0.001 4.2% 10.4% 0.166 
Stroke/TIA/Arterial embolism 12 (2.8) 4 (2.4) 1.0 2.8% 1.4% 0.598 
 
Variables are presented as frequency (percentage). MACCE indicates major adverse cardiac and cerebrovascular events; TIA: transient ischemic 
attacks; BARC: Bleeding Academic Research Consortium. 
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Figure legends 
  
Figure 1. Kaplan-Meier analysis with log-rank test: Freedom from major bleeding (BARC 3a, b, c, 
and 5) at 90 days follow-up after percutaneous coronary intervention with stent implantation in 
patients with atrial fibrillation according to VKA-TT (black line) and LMWH-TT (grey line) at 
discharge.  
 
Figure 2. Kaplan-Meier analysis with log-rank test: Freedom from major cardiac and 
cerebrovascular events (MACCE) after percutaneous coronary intervention with stent 
implantation in patients with atrial fibrillation according to VKA-TT (black line) and LMWH-TT 
(grey line) at discharge. 
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Figure 2 
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Highlights 
 
 
 Bridging treatment with low-molecular-weight heparin (LMWH) has been the standard 
recommendation for patients with atrial fibrillation (AF) undergoing percutaneous 
coronary intervention (PCI). 
 In this large, prospective, real-world population we prospectively assessed the effect of 
LMWH-bridging therapy vs. uninterrupted oral anticoagulation therapy on thrombotic 
and bleeding events in this patient subset with an indication for anticoagulation plus 
dual antiplatelet therapy. 
 Patients with AF undergoing PCI discharged on LMWH-triple therapy had a significantly 
higher risk for major bleeds in comparison to patients discharged on uninterrupted oral 
anticoagulation and dual antiplatelet therapy.  
 LMWH-bridging therapy appeared harmful in this subset of patient on oral 
anticoagulation. 
